Short-acting β 2 -agonist use and asthma exacerbations in Swedish children: A SABINA Junior study.
Erik MelénBright Ibeabughichi NwaruFredrik WiklundSofie de Fine LichtGunilla TelgEkaterina MaslovaRalf J P van der ValkTrung N TranMagnus EkströmChrister JansonPublished in: Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology (2022)
High SABA use was associated with increased asthma exacerbation risk in children, particularly in those without comorbid atopic diseases, emphasizing the need for asthma medication reviews and reformative initiatives by caregivers and healthcare providers on SABA use.